MAGIC Cell-5-Combicytokine Trial

Single Center, Prospective, Randomized, Partly-Double Blinded, Controlled Trial to Assess the Safety and Feasibility of Intracoronary Cell Infusion Mobilized With G-CSF and Darbepoetin and Their Effects on Improvement of Cardiac Function in Patients With Myocardial Infarction: Myocardial Regeneration and Angiogenesis in Myocardial Infarction With G-CSF and Erythropoietin Mobilization and Intra-Coronary Cell Infusion -5-Combination Cytokine Therapy Trial

Status

UNKNOWN

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00501917

Acronym

MAGIC Cell-5

Enrollment

116

Registered

2007-07-16

Start date

2007-03-31

Completion date

2010-02-28

Last updated

2007-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction

Keywords

acute myocardial infarction

Brief summary

Combination use of darbepoetin and G-CSF will improve left ventricular systolic function in patients with acute myocardial infarction who receive intracoronary infusion of mobilized peripheral blood stem cell in comparison with patient who treated with conventional measures and who received intracoronary infusion of mobilized peripheral blood stem cell by G-CSF alone.

Interventions

DRUGG-CSF with/without darbepoetin, peripheral blood stem cell infusion

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

15 Years to 80 Years

Healthy volunteers

Inclusion criteria

* ST elevation acute myocardial infarction * \< 80years * successful revascularization of culprit vessel

Exclusion criteria

* uncontrolled congestive heart failure * uncontrolled myocardial ischemia * uncontrolled ventricular arrhythmia * malignancy * serious hematologic disease * chronic renal failure

Design outcomes

Primary

Measure	Time frame
change of left ventricular ejection fraction measured by cardiac MRI	6, 12, and 24month

Secondary

Measure	Time frame
wall motion score index exercise capacity BNP	6,12, 24month

Countries

South Korea

Contacts

Primary ContactHyo-Soo Kim, MD PhD

hyosoo@snu.ac.kr82-2-2072-2226

Backup ContactHyun-Jae Kang, MD PhD

nowkang@snu.ac.kr82-2-2072-2279

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 29, 2026